Bristol Myers Squibb is already juggling several important drug launches. But that doesn’t mean the company can’t take on another near-to-market asset now through an M&A deal, CEO Giovanni Caforio said. “I don’t see commercial capacity as a factor that would constrain our ability” to look at business development around later-stage assets, the outgoing chief executive said during an investor call. Striking deals remains Bristol’s “top priority,” CFO David Elkins said during the call. BMS will continue to look for deals in fields where the company has deep R&D and commercial expertise, regardless of the stage of the program, he said.
Read the full article: Bristol’s Multiple New Launches Won’t Stop It from Scouting for M&A Deals, CEO Says //
Source: https://www.fiercepharma.com/pharma/bristol-myers-still-looks-late-stage-ma-deals-despite-multiple-new-launches-ceo